These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20713596)

  • 121. Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.
    Wrensch F; Ligat G; Heydmann L; Schuster C; Zeisel MB; Pessaux P; Habersetzer F; King BJ; Tarr AW; Ball JK; Winkler M; Pöhlmann S; Keck ZY; Foung SKH; Baumert TF
    Hepatology; 2019 Nov; 70(5):1506-1520. PubMed ID: 31062385
    [TBL] [Abstract][Full Text] [Related]  

  • 122. The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication.
    Zhuang X; Magri A; Hill M; Lai AG; Kumar A; Rambhatla SB; Donald CL; Lopez-Clavijo AF; Rudge S; Pinnick K; Chang WH; Wing PAC; Brown R; Qin X; Simmonds P; Baumert TF; Ray D; Loudon A; Balfe P; Wakelam M; Butterworth S; Kohl A; Jopling CL; Zitzmann N; McKeating JA
    Nat Commun; 2019 Jan; 10(1):377. PubMed ID: 30670689
    [TBL] [Abstract][Full Text] [Related]  

  • 123. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.
    Wrensch F; Crouchet E; Ligat G; Zeisel MB; Keck ZY; Foung SKH; Schuster C; Baumert TF
    Front Immunol; 2018; 9():1436. PubMed ID: 29977246
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.
    Keck ML; Wrensch F; Pierce BG; Baumert TF; Foung SKH
    Front Immunol; 2018; 9():1194. PubMed ID: 29904384
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
    Mesalam AA; Desombere I; Farhoudi A; Van Houtte F; Verhoye L; Ball J; Dubuisson J; Foung SKH; Patel AH; Persson MAA; Leroux-Roels G; Meuleman P
    Virology; 2018 Jan; 514():30-41. PubMed ID: 29128754
    [TBL] [Abstract][Full Text] [Related]  

  • 127. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8
    Wolski D; Foote PK; Chen DY; Lewis-Ximenez LL; Fauvelle C; Aneja J; Walker A; Tonnerre P; Torres-Cornejo A; Kvistad D; Imam S; Waring MT; Tully DC; Allen TM; Chung RT; Timm J; Haining WN; Kim AY; Baumert TF; Lauer GM
    Immunity; 2017 Oct; 47(4):648-663.e8. PubMed ID: 29045899
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.
    Solis M; Velay A; Porcher R; Domingo-Calap P; Soulier E; Joly M; Meddeb M; Kack-Kack W; Moulin B; Bahram S; Stoll-Keller F; Barth H; Caillard S; Fafi-Kremer S
    J Am Soc Nephrol; 2018 Jan; 29(1):326-334. PubMed ID: 29042457
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children.
    Arthur Huang KY; Chen MF; Huang YC; Shih SR; Chiu CH; Lin JJ; Wang JR; Tsao KC; Lin TY
    Nat Commun; 2017 Oct; 8(1):762. PubMed ID: 28970483
    [TBL] [Abstract][Full Text] [Related]  

  • 131. A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    Chang CC; Hsu HJ; Yen JH; Lo SY; Liou JW
    PLoS One; 2017; 12(5):e0177383. PubMed ID: 28481946
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
    Khera T; Todt D; Vercauteren K; McClure CP; Verhoye L; Farhoudi A; Bhuju S; Geffers R; Baumert TF; Steinmann E; Meuleman P; Pietschmann T; Brown RJ
    Antiviral Res; 2017 Mar; 139():129-137. PubMed ID: 28062191
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Viral evasion and challenges of hepatitis C virus vaccine development.
    Pierce BG; Keck ZY; Foung SK
    Curr Opin Virol; 2016 Oct; 20():55-63. PubMed ID: 27657659
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.
    Keck ZY; Wang Y; Lau P; Lund G; Rangarajan S; Fauvelle C; Liao GC; Holtsberg FW; Warfield KL; Aman MJ; Pierce BG; Fuerst TR; Bailey JR; Baumert TF; Mariuzza RA; Kneteman NM; Foung SK
    Hepatology; 2016 Dec; 64(6):1922-1933. PubMed ID: 27641232
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
    Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
    Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.
    Urbanowicz RA; McClure CP; King B; Mason CP; Ball JK; Tarr AW
    J Gen Virol; 2016 Sep; 97(9):2265-2279. PubMed ID: 27384448
    [TBL] [Abstract][Full Text] [Related]  

  • 138. New perspectives for preventing hepatitis C virus liver graft infection.
    Felmlee DJ; Coilly A; Chung RT; Samuel D; Baumert TF
    Lancet Infect Dis; 2016 Jun; 16(6):735-745. PubMed ID: 27301929
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
    Fauvelle C; Colpitts CC; Keck ZY; Pierce BG; Foung SK; Baumert TF
    Expert Rev Vaccines; 2016 Dec; 15(12):1535-1544. PubMed ID: 27267297
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
    Colpitts CC; Baumert TF
    Hepatol Int; 2016 Sep; 10(5):741-8. PubMed ID: 27048616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.